信邦制药涉单位行贿被审查起诉，核心子公司与旧案交织凸显多重风险

Core Viewpoint - Xinfang Pharmaceutical is facing multiple pressures related to legal, operational, and governance issues due to its involvement in a bribery case, which has been transferred to the prosecution for review [1][6]. Legal Risks - If the unit bribery charge is established, the company may face fines ranging from over 100,000 yuan to twice the amount of the crime, while responsible personnel could face imprisonment and fines [2][7]. - The company acknowledges that this situation may impact its brand reputation, business expansion, and future development [2][7]. - If the income involved is deemed illegal, the company may face risks of confiscation, complicating shareholder claims if no false disclosures are found [2][7]. Core Asset Concerns - The bribery case is closely linked to its subsidiary, Keke Pharmaceutical, which was previously investigated for bribery [3][8]. - Keke Pharmaceutical generated revenue of 2.278 billion yuan, net profit of 94.5 million yuan, and net assets of 2.482 billion yuan in 2023, accounting for significant portions of Xinfang's overall performance [3][8]. Governance Issues - The acquisition of Keke Pharmaceutical in 2014 involved former chairman An Huailue, who has been implicated in corruption cases [4][9]. - An Huailue's role in key transactions and ongoing legal issues raises concerns about the company's governance transparency and independence [4][9]. Current Operational Pressures - For the first three quarters of 2025, Xinfang reported revenue of 4.266 billion yuan, a decline of 6.55%, and a net profit of 152 million yuan, down 13.74% [5][10]. - The combination of weak business growth and ongoing legal investigations poses challenges to the company's strategic stability and market confidence [5][10].